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Abstract Primary antibody deficiency disorders (PADs) can
have an excellent outlook if diagnosed early and treated
appropriately, but require lifelong treatment with immuno-
globulin replacement. Some carry risks of inflammatory com-
plications even with optimal treatment. Quality of life (QoL)
and the psychological impact of PADs has been relatively little
studied, particularly in children. The purpose of this study was
to evaluate QoL and psychological impact in a large group of
children affected by a range of PADs, as well as a group with
transient hypogammaglobulinemia of infancy (THI). Both
parental and, where appropriate, child ratings, were collected
using standardised questionnaires (PedsQL and SDQ). Higher
rates of psychological difficulties, particularly emotional and
peer-relationship difficulties were found in children with PAD
when compared with healthy controls. Quality of life was
poorer than in healthy controls, and also worse than in chil-
dren affected by diabetes mellitus. Variations in QoL and the
degree of psychological difficulties were found between spe-
cific diagnostic groups, with children affected by THI being
amongst those with the lowest scores for QoL. Further studies
are needed to corroborate and extend these findings, but this
study confirms previous findings that primary antibody defi-
ciency has a significant impact on quality of life and psycho-
logical well-being, and additionally suggests that the impact
varies according to severity of the underlying condition. For
those with significant difficulties psychological intervention at
an early stage may be beneficial.
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Introduction
Primary antibody deficiency syndromes (PADs) account for
the majority of primary immunodeficiency disorders [1].
Common Variable Immunodeficiency (CVID) occurs most
frequently in the population, but in children single gene dis-
orders are relatively more frequent, including X-linked agam-
maglobulinemia (XLA), hyper-IgM syndromes, rare autoso-
mal recessive agammaglobulinemias, and a variety of less
clearly defined disorders where antibody deficiency is the
major defect. Some children who have undergone stem cell
transplantation or gene therapy for severe forms of PID have
incomplete immune reconstitution and have long-term anti-
body deficiency.
All forms of PAD carry a risk of long-term organ damage
as a result of repeated or chronic infections. Some are also
associated with other complications, including gastro-
intestinal inflammatory disorders, autoimmune disease, liver
disease, granulomatous disease, lymphoproliferative disease,
and occasionally malignancy. However, with early diagnosis
and optimal treatment the long-term outlook can be excellent
[2].
The mainstay of treatment for PAD is immunoglobulin
(antibody) replacement. Immunoglobulin can be administered
intravenously (IVIg) every 3–4 weeks, or subcutaneously
(SCIg) every 1–2 weeks. The aims of treatment are to main-
tain good health, prevent infections, prevent or arrest progres-
sion of complications, and maintain good quality of life. In
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recent years increased experience and more aggressive treat-
ment with immunoglobulin, as well as better awareness and
earlier diagnosis have led to improvements in the long-term
outlook for physical health in patients with PADs [3]. How-
ever, the impact of PAD and its treatment on quality of life
(QoL) has been relatively little studied. PADs carry potentially
wide-ranging impacts psychologically, emotionally and prac-
tically for the whole family. Affected children (and their
families) have to come to terms with a lifelong medical
condition that requires treatment involving regular needles
and considerable time input. In some disorders the long term
outlook is more uncertain because of the risk of non-infective
complications.
Children affected by transient hypogammaglobulinemia of
infancy (THI) suffer from repeated infections in the first few
years of life, and have low immunoglobulin levels that nor-
malise over time [4]. Serious life-threatening infections are
rare in this group, and immunoglobulin replacement is not
usually indicated. Nevertheless their general health can be
significantly affected. There is no diagnostic test to confirm
THI, and the diagnosis can only be certain in retrospect, once
immunoglobulin levels have normalized.
The aims of this study were to assess the impact on quality
of life and on psychological, emotional and behavioural
wellbeing in children affected by a range of PADs. The study
included both child self-rating and parent-rating of the impact
on the child’s QoL. Diagnostic categories of antibody defi-
ciency were also compared to determine whether potentially
more serious conditions have a greater impact..
Methods
Children attending a specialist/tertiary immunology service
with known or suspected antibody deficiency were invited to
take part in a study investigating a range of aspects of PAD in
children. Informed consent, and assent where appropriate, was
obtained from all participants.
For the purposes of this study children were eligible if they
were affected by a primary immunodeficiency requiring long-
term immunoglobulin replacement, and in whom corrective
treatment by stem cell transplantation or gene therapy was not
indicated or, in the case of boys with CD40 ligand deficiency,
no donor was available. In addition a small group of children
with THI were studied.
Participants
85 families were approached to take part in the wider study
and 80 % consented to participate. Reasons for non-
participation included families repeatedly not attending ap-
pointments, not having time to complete measures and
perceiving that the study would involve extra visits to hospital.
68 children, 48 boys (70 %) and 20 girls (30%) enrolled in the
study. 43 children aged 4 years and above were eligible for the
psychological difficulties and QoL study. These included 28
boys (65 %) and 15 girls (35 %), with a mean age of 10 years
8 months, range 5 – 16 years. One girl was withdrawn after the
enrolment visit because the family no longer wished to
participate.
37 children were receiving long-term immunoglobulin re-
placement, 35 subcutaneously, and 2 intravenously. Addition-
ally, 1 child had received subcutaneous immunoglobulin for
approximately 10 years and was able to discontinue during the
course of the study because of normalisation of immunoglob-
ulin levels. 5 further children with probable THI were not on
replacement immunoglobulin.
Primary diagnosis is shown in Table I. For analysis of
results by diagnosis the children with ‘CVID’ and ‘possible
CVID’ have been amalgamated as ‘Combined’.
Measures
Standardised self-report questionnaires were used to assess
psychological difficulties and quality of life.
Questionnaires were given to the parents and child (if
appropriate) at the enrolment visit for the study; these visits
were timed to coincide with routine follow-up out-patient
clinic appointments, and did not take place on the same day
Table 1 PID diagnosis in study participants
Diagnosis Number Percent
Confirmed CVID1 13 30
Possible CVID2 3 7
Other PID3 9 21
X-Linked Agammaglobulinemia 5 12
Antibody deficiency post Bone Marrow Transplant
for PID4
4 9
CD40 Ligand deficiency (no BMT) 5 3 7
(Probable) Transient hypogammaglobulinemia of
Infancy (THI)
6 14
TOTAL 43 100
1According to European Society for Immunodeficiency (ESID) diagnos-
tic criteria
2 Diagnosis not confirmed but suggestive according to ESID criteria
3 ICF syndrome (1), Activation-induced cytidine deaminase deficiency
(autosomal recessive hyper-IgM deficiency) (1), Nijmegen breakage
syndrome (1), Emanuel syndrome (chromosome 11/22 balanced translo-
cation) with hypogammaglobulinemia (1), IPEX-like syndrome (1), un-
defined (4)
4 X-linked severe combined immunodeficiency (2), PNP deficiency (1),
undefined (1)
5 No donor available for stem cell transplantation
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as immunoglobulin infusions. Assistance was provided by the
research nurse if necessary.
Psychological Difficulties Strengths and difficulties question-
naire (SDQ) [5].
This is a widely used standardised screening measure for
common psychological difficulties in childhood and has been
shown to have good reliability and validity. One parent of all
children aged 4 – 16 completed the parent report version of the
questionnaire, and children aged 11 or above completed the
self-report version. This questionnaire measures 4 areas of
psychological difficulties: conduct (behaviour) problems,
emotional difficulties, hyperactivity, and peer relationship
difficulties, which can be combined to give a total difficulties
score. In addition, it includes a measure of prosocial behavior
– this is a measure of positive behaviour and is not included in
the total difficulties score. It also includes an impact score
which measures the perceived impact of the child’s difficulties
on their day to day life at home and at school. Children under
the age of 4 were not included because younger children do
not present with the types of psychological difficulties
assessed by this measure.
Quality of Life Pediatric Quality of Life (PedsQL) [6, 7].
This is a widely used generic standardised measure of
health related quality of life. It includes subscales measuring
quality of life in four domains: physical, emotional, social and
school. Parents of children aged 5 and above completed the
parent report version of the questionnaire and children aged 5
and above completed the self-report version. The results from
this study were compared with the normative values
established in the UK standardization study of this measure
[17], because these were considered to be the most appropriate
comparison group, given the measure has not been used
routinely for other patient groups within the hospital.
Illness Severity
Severity of antibody deficiency can be assessed in various
ways. These include the long term impact of the condition and
the likelihood that it will result in serious health problems as
an adult, the number and frequency of infections and use of
antibiotics, and the impact of the illness on quality of life as
perceived by the child or parent.
Since there is no standardized measure available for rating
severity of an immunodeficiency, a 5 point clinician severity
rating scale was developed for this study, with 5 indicating the
most severe, and 1 the least severe conditions (see Online
Resource 1). Severity ratings were based on clinician’s assess-
ments of whether or not the condition was lifelong, and the
presence of, or potential for, complications of the underlying
PAD. The rating scale was shown to be reliable by assessing
inter-rater reliability between a consultant immunologist and
an experienced clinical nurse specialist (r=0.83, p<0.001).
Ethical approval for the study was granted by the Great
Ormond Street Hospital/Institute of Child Health/UCL ethics
committee.
Results
Psychological Outcome
43 parents and 19 children completed the SDQ. Figure 1
shows mean total SDQ scores for both parent and child reports
for psychological difficulties. Figures 2 and 3 show mean
parent and child SDQ score for the same four individual
SDQ subscales. All scores were compared to normative values
for the UK population. In order to focus more specifically on
children with long-term antibody deficiency these analyses
were also carried out excluding the THI group, but this did not
affect the overall results, so data are presented for the whole
cohort.
Parents of children with PAD reported significantly higher
overall rates of psychological difficulties compared to norma-
tive values for healthy children. By subscale children with
PAD had higher rates of emotional difficulties, peer relation-
ship difficulties and hyperactivity, but no significant differ-
ence in behavioural (conduct) difficulties. There were no
differences in ratings of prosocial behaviour (data not shown).
Children’s own ratings for total difficulties were higher
than those of healthy children but this difference did not reach
significance (p=0.1). For individual subscale ratings chil-
dren’s own scores for emotional difficulties were significantly
higher than those for healthy children (p<0.05).
Parent and child ratings on the SDQ were significantly
correlated (r=0.63, p<0.01) indicating a high level of agree-
ment on psychological difficulties.
Quality of Life
43 parents and 39 children completed the PedsQL.
(i) Whole group
Figure 4 shows parent-rated quality of life for children with
PAD compared with healthy children and also with children
affected by diabetes mellitus reported in the UK
standardisation study for the PedsQL (Upton et al. 2005).
These children were chosen as an illness comparison group
because diabetes mellitus is also a lifelong condition that
requires regular medication, including frequent needles and
blood tests.
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Children’s own ratings of overall quality of life and sub-
scale scores are shown in Fig. 5, also compared with healthy
children and children with diabetes.
Parents of children with PAD reported significantly lower
quality of life in their children on all the subscales of the
PedsQL when compared with healthy UK children. In addi-
tion, parents’ ratings were lower than parents of children with
diabetes for all subscales, with the exception of the emotional
subscale.
A similar pattern was observed for child ratings of QoL;
children with PAD reported significantly lower QoL com-
pared to healthy children on all subscales (including the
overall score) of the PedsQL, and lower scores than chil-
dren with diabetes on all subscales except the emotional
subscale.
Parent and child ratings on PedsQL were very strongly
correlated (r=0.79) indicating high levels of agreement on
quality of life between parents and children.
(ii) By diagnostic group
Figures 6 and 7 show the mean overall QoL rating for
parents and children respectively, by diagnostic group. The
numbers of children in each group were small, so no statistical
analysis was possible, and results should therefore be
interpreted with caution. The ‘Other PID’ group reported the
lowest quality of life scores.
Severity of Illness
Mean clinician severity ratings for each of the diagnostic groups
is shown in Fig. 8. Comparison of these scores with the parent
and child reported QoL and parental reports of psychological
difficulties reveals very low correlation (parent or child report
of quality of life: r=–0.09 and r=–0.26 respectively; parental
report of psychological difficulties: r=0.19) In particular, whilst
the clinician severity rating for THI was the lowest of all the
Fig. 1 Mean total parent and
child SDQ scores for
psychological difficulties
(including conduct, emotional,
peer relationship and
hyperactivity scores). Higher
scores indicate more difficulties,
with a maximum possible score of
40. Error bars indicate 95 %
confidence intervals; and
statistically significant differences
are indicated by an asterisk *
Fig. 2 Mean parent rated SDQ
individual subscale scores.
Higher scores indicate higher
levels of psychological
difficulties with a maximum
possible score of 10. Error bars
indicate 95 % confidence
intervals; statistically significant
differences are indicated by an
asterisk *
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conditions, both children and parents in this group reported
relatively poor QoL and high rates of psychological difficulties,
second only in severity to the ‘Other PID’ group.
Discussion
This current study shows that children with a range of primary
antibody deficiencies have higher rates of psychological dif-
ficulties compared to healthy children. This is consistent with
findings in many other types of chronic illness in childhood,
where children have also been shown to be at higher risk of
psychological disorders [8]. Specifically, children in this study
had higher rates of emotional difficulties, peer relationship
difficulties and hyperactivity, but did not have higher rates of
behavioural (conduct) disorders. These differences are clini-
cally meaningful and equivalent to moderate to large effect
sizes, representing the highest (most affected) 20 % of chil-
dren in the general population in terms of levels of psycho-
logical difficulties. This pattern of psychological difficulties is
in contrast to studies of children in the general population,
where the most common types of difficulty children experi-
ence are conduct or behavioural problems. However, it is
consistent with studies in children with other types of primary
immunodeficiencies [9, 10], which have also found higher
rates of emotional and or peer relationship difficulties in
affected children. At present there are no intervention studies
specifically with children with these types of medical condi-
tions. However, it is likely that treatments based on family
oriented cognitive behavioural principles, which have been
found to be effective with unaffected children with these types
of psychological difficulties may be appropriate, but further
research is needed on evaluating treatment approaches
Both children and parents reported lower levels of QoL
than healthy children, but, perhaps more surprisingly, they
also reported lower QoL than a comparison group of children
with diabetes mellitus. This comparison group was chosen
because it has similar implications to PAD, being a lifelong
disorder, requiring treatment with regular needles, and carry-
ing significant risks of life-threatening and life-limiting com-
plications. The finding of worse QoL in children with PAD
than those with diabetes is unexpected in light of the belief
Fig. 3 Mean child rated
individual SDQ subscale scores.
Higher scores indicate higher
levels of psychological difficulty
with a maximum possible score of
10.. Error bars are only shown for
the emotional subscale; the
intervals for other subscales are
too large due to the small number
of children who were old enough
to complete this measure.
Statistically significant
differences are indicated by an
asterisk *
Fig. 4 Mean parent rated overall quality of life and subscale scores for
childrenwith PAD, compared both with healthy children andwith a group
of children with diabetes mellitus included in the UK standardization
study of the PedsQL [17]. Higher scores indicate better QoL and there is a
maximum score of 100. Error bars indicate 95 % confidence intervals;
statistically significant differences are indicated by an asterisk *
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amongst clinicians that QoL can be ‘normal’ in children with
PADs provided that treatment is optimised. A noticeable
finding is that scores relating to school were particularly
low; which might reflect a sense of isolation resulting from
fear of infections or of difference from peers. The data for the
comparison group of children with diabetes was taken from
the UK standardization of the quality of life measure [7] but in
future research it would be important to collect data on a
matched control group if possible.
A possible confounding factor is that timing of completion
of questionnaires in relation to immunoglobulin infusions
could have had an impact on responses, particularly if there
were associated adverse reactions. However, none of the
children received their infusions on the day of completing
questionnaires, and there were no significant adverse reactions
in any of the participants during the course of the study. All
children were well-established and stable on long-term
treatment
A small number of previous studies have investigated QoL
in PADs. Several have focussed on comparison between IVIg
and SCIg, demonstrating broadly improved QoL in both
adults and children who switch from IV to SC treatment,
particularly when treatment is given at home [11–13]. Other
studies have compared QoL in adults and children affected by
PADs with healthy controls and other chronic diseases. These
suggest that QoL in adults with CVID is worse than in healthy
controls and patients with congestive heart failure or diabetes
mellitus [14, 15], but QoL in adult males with XLA is similar
to healthy controls [16, 17].
Whilst most other studies of children with PIDs have also
shown a significant impact on QoL when compared to healthy
controls, results have varied when compared to other health
conditions. Zebracki et al. [18] found that parents reported
lower QoL in children with various PIDs (all requiring IVIg)
than in healthy controls, but similar to children with juvenile
arthritis. Mozaffari et al. [19] found self-reported QoL in
children with PIDs was lower than for healthy aged-matched
controls. A study of children and adolescents affected by X-
linked agammaglobulinemia, which included both parental
and self-reporting, showed poorer QoL in affected boys than
in healthy controls, but better than in children with rheumatic
disorders [20]. These paediatric studies have been performed
in populations from diverse geographical backgrounds, and
the availability of early diagnosis and access to optimal treat-
ment may vary, but the findings show consistently that quality
of life in children with PID is worse in all groups than in
Fig. 5 Mean child rated overall quality of life and subscale scores
compared both with healthy children and with a group of children with
diabetes mellitus included in the UK standardization study of the PedsQL
[17]. Higher scores indicate better QoL and there is a maximum score of
100.. Error bars indicate 95 % confidence intervals; statistically signifi-
cant differences are indicated by an asterisk *
Fig. 6 Mean parent rated overall
quality of life by diagnostic group
Higher scores indicate better QoL
and there is a maximum score of
100. For analysis of results by
diagnosis the children with
‘CVID’ and ‘possible CVID’
have been amalgamated as
‘Combined’
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healthy controls. Future research should focus on determining
what factors are related to variation in QoL, such as the impact
of the effectiveness of treatment in improving QoL.
A range of antibody deficiency disorders were included in
the study. Variations in QoL were observed between diagnos-
tic groups but the small numbers in each group did not permit
assessment of significance. At the moment, these results must
be interpreted with caution given the small numbers of partic-
ipants in this sample, however, this is an important area to
study in future and may explain variations in impact of PADs
on QOL seen in previous studies. For example, boys affected
by XLA and children in the post-BMT group reported higher
levels of QoL, consistent with the low incidence of non-
infectious complications in these two groups. Children with
CVID and ‘other’ PAD reported lower QoL, consistent with
the higher incidence of other complications they experience.
However, surprisingly, for the small group of boys with CD40
ligand deficiency (which carries a high risk of liver disease
and other complications) parental QoL ratings were higher
than for all other groups. Conversely, parent reports for the
group with ‘probable THI’ reported lower QoL than all groups
except 'other PAD'. THI is not associated with serious infec-
tions or complications, and affected children are usually
managed with antibiotics. They are monitored with regular
blood tests to ensure that immunoglobulin levels are improv-
ing, and reassurance to parents that the likely outcome will be
normality. However, these findings suggest that the impact of
THI on children and families is greater than expected, and
may raise questions about management of such children. It is
also possible that this reflects the relatively short time that the
parents have had to adjust to their child’s condition, since the
children with THIwere somewhat younger and therefore there
will have been a shorter time since diagnosis. Additionally the
uncertainty about the long-term outlook may contribute to the
findings. Further studies are needed in this group to determine
if this result is replicated and to establish whether the impact is
significant enough in some cases to justify more aggressive
treatment – in particular whether more of these children might
benefit from short to medium-term immunoglobulin
replacement.
There have been no previous attempts to correlate QoL
with severity of underlying disorders. Objective ratings of
severity of illness by clinicians revealed discrepancies with
the child and parents’ ratings of the impact onQoL. According
to clinician ratings, CD40 ligand deficiency is the ‘most
severe’ of the PAD disorders in this study, while XLA, CVID,
Fig. 7 Mean child rated overall
quality of life by diagnostic group
Higher scores indicate better QoL
and there is a maximum score of
100. For analysis of results by
diagnosis the children with
‘CVID’ and ‘possible CVID’
have been amalgamated as
‘Combined’
Fig. 8 Mean clinician severity
ratings for each of the diagnostic
groups. The maximum score is 5,
indicating most severe. For
analysis of results by diagnosis
the children with ‘CVID’ and
‘possible CVID’ have been
amalgamated as ‘Combined’
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other PAD, and post-BMT PAD are rated as intermediate, and
THI is significantly milder. These perceptions do not tally
with the QoL data, and this illustrates the importance of
considering patient/parent reported outcomes, as well as more
‘objective’ ratings based on clinical experience.
When the study was established it was hoped that compar-
isons could be made between children receiving IVIg and
SCIg. However, the majority of children on long-term immu-
noglobulin at this centre are on SCIG, only 2 children in this
cohort receiving their immunoglobulin intravenously. It was
therefore not possible to compare the two groups in terms of
QoL or psychological difficulties. Previous research has dem-
onstrated improved QoL for both children and adults when
moving from IVIG to SCIG, with emphasis on the impact of
home versus hospital-based therapy.
There are limitations to this study which mean the results
do need to be seen as preliminary; future research should
address these if possible. Firstly, the results from the PAD
group were compared with normative values for the standard-
ized measures rather than with a matched control group of
children. Future research should include an appropriate con-
trol group, for example contemporaneous controls with other
medical conditions treated at the same hospital. In addition
this was a cross sectional study so it was not possible to relate
results to the child’s medical treatment, and in particular
whether infections were well controlled and if they were
receiving optimal treatment. Although the overall numbers
of patients was relatively high compared to other studies of
children with these rare conditions, the numbers in individual
diagnostic groups and age groups were relatively small, lim-
iting the comparisons that could be made. Future studies
should ideally have enough power to investigate these factors,
which may have an important impact on both psychological
outcome and QoL but could not be included in this study.
Conclusions
This study confirms previous findings that primary antibody
deficiency has a significant impact on quality of life and
psychological well-being, and additionally suggests that the
impact varies according to severity of the underlying condi-
tion. For children with significant difficulties psychological
intervention at an early stage may be beneficial.
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